It may have been BrightInsight’s first BIO International Conference last week but will definitely not be our last. It was great to see colleagues and clients again in person, make new connections and have discussions on the trends and market dynamics in biopharma and medtech. What an outstanding event—kudos to the entire team at #BIO2022 on a fantastic conference that brought the community together in San Diego for 4 days of engaging discussions, networking and learning. And thanks to all who stopped by our booth.
We started off the week strong, launching our digital Disease Management Solution for biopharma and medtech. Built on our compliant BrightInsight® Platform on Google Cloud, the Disease Management Solution meets biopharma and medtech customers’ core needs out-of-the-box to support the highest regulated digital health Software as a Medical Device (SaMD) classifications. Cathy Zaremba, BrightInsight’s Director of Product Marketing, offered dozens of demos in our spectacular booth (Donovan Ho for the win!) explaining how our suite of configurable digital applications can help biopharma and medtech companies speed time to market, improve outcomes and grow revenue.
The configurable suite of digital applications helps biopharma differentiate their top brands with comprehensive tools that enhance the patient experience and features:
For more details on the solution, check out this MedCity News article.
Karl Hick, former Chief Digital and Information Officer at Takeda, and member of the BrightInsight Advisory Council was with us at BIO, and noted, “For biopharma to build and launch regulated digital solutions efficiently and effectively, it will become critical to engage partners like BrightInsight with the experience, robust Professional Services, and proven platform and solutions to ensure speed to market in a compliant manner, at scale.”
Nick Basta, editor emeritus of Pharmaceutical Commerce spoke with Kal Patel about our Disease Management Solution and Dennis Dailey reported on the launch in mHealth Times coverage of BIO 2022.
On the second day of BIO, our CEO and co-founder, Kal Patel, MD, MBA, joined Brad Gescheider, Sanofi’s Global Head-Digital Innovation and Patient Services, Immunology, James Lu, MD, PhD, CEO and Co-Founder of Helix and Wainwright Fishburn, Global Chair, Digital Health at Cooley for a Panel discussion entitled, Partnering Strategies for Success in Digital Health.
Brad pointed out, “Sanofi believes that digital innovation can transform the discovery, development, and delivery of medicine.” And biopharma doesn’t have to go it alone, as Brad noted, “We partnered with BrightInsight to build the next generation of digital disease management solutions that will enable us to impact every step of the patient journey.”
Many in biopharma are deciding between, build versus buy. But as Kal Patel pointed out, “Partnering with a digital health company like BrightInsight is not a buy versus build discussion. It’s a build versus build discussion. Biopharma should build out their digital capability, but also identify which areas they want to partner for, such as higher regulated use cases like Software as a Medical Device."
It’s not an either or.
Kal explains, “Software as a Medical Device (SaMD) will be foundational to generating value around therapies and devices and it’s at the heart of what we do.”
Companies like Sanofi, and other BrightInsight customers like CSL Behring, Roche, UCB and Novo Nordisk know that it’s important to make the patient experience central to your digital strategy. Digital tools that engage, support and track the patient journey can enable more personalized therapies, increase brand loyalty, drive better communication between patients and providers and improve outcomes. Biopharma can demonstrate value by leveraging Real World Data to extend patent life, improve reimbursement and expand labeling.
We were excited to partner with McKinsey & Company and Google Cloud to host a first-of-its-kind Digital Health Thought Leadership Summit. The intimate and engaging evening event brought together some of the world’s top life sciences and digital executives from Sanofi, Otsuka, Dexcom, J&J, Roche, Kyowa Kirin, Mayo Clinic among others to discuss leveraging the cloud for direct patient engagement.
It was an incredibly productive and busy four days in San Diego at BIO. Sending a huge shout out to the entire BrightInsight team for an incredibly successful event. Thank you all for your great work and tireless efforts. Can’t wait for BIO 2023!